格隆汇10月9日丨重药控股(000950.SZ)公布，截至2025年9月30日，公司通过股份回购专用证券账户以 集中竞价交易方式累计回购股份数量为15,406,600股，约占公司总股本的0.8915%；最高成交价为5.48 元/股、最低成交价为5.01元/股，支付总金额为80,998,765.98元（不含交易费用）。本次回购符合法律 法规、规范性文件的有关规定及公司回购股份方案的要求。 ...

Company Summary - Zhongyao Holdings (SZ 000950) announced on October 9 that as of September 30, 2025, it has repurchased approximately 15.41 million shares, accounting for about 0.8915% of the total share capital, with a total expenditure of approximately 81 million yuan [1] - The highest transaction price during the repurchase was 5.48 yuan per share, while the lowest was 5.01 yuan per share [1] - As of the report date, Zhongyao Holdings has a market capitalization of 8.9 billion yuan [1] Industry Overview - For the first half of 2025, the revenue composition of Zhongyao Holdings was as follows: pharmaceutical wholesale accounted for 94.81%, pharmaceutical retail for 4.73%, and other businesses for 0.46% [1]

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 301015 | 百洋医药 | 27.17 | -2.96% | 5.74万 | 1.58亿 | | 301584 | C建发致 | 28.15 | -2.90% | 21.71万 | 6.15亿 | | 600833 | 第一医药 | 13.38 | -2.76% | 8.11万 | 260'T | | 301126 | 达嘉维康 | 11.13 | -2.37% | 4.04万 | 4537.69万 | | 603108 | 润达医疗 | 15.70 | -1.88% | 19.17万 | 3.00亿 | | 000705 | 浙江震元 | 9.78 | -1.41% | 13.46万 | 1.31亿 | | 002462 | 章章点 | 13.69 | -0.58% | 4.41万 | 6013.33万 | | 300937 | 药易购 | 26.53 | -0.49% | 1.29万 | 3415.25万 | | 600538 | 国发股份 ...

重药控股股份有限公司 关于回购股份进展的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 重药控股股份有限公司（以下简称"公司"）分别于 2025 年 7 月 10 日、2025 年 7 月 28 日召开第九届董事会第十五次会议、2025 年第三次临时股东会，审议 通过了《关于回购公司股份的议案》，同意公司使用自有资金及股票回购专项贷 款，通过深圳证券交易所交易系统以集中竞价交易方式回购公司已发行的人民币 普通股（A 股），用于减少公司注册资本。本次用于回购股份的资金总额不低于 人民币 8,000 万元（含本数），不超过人民币 10,000 万元（含本数），回购价格 不超过人民币 6.6 元/股（含本数），回购期限为自股东会审议通过回购股份事项 之日起 12 个月内。具体内容详见公司在巨潮资讯网（www.cninfo.com.cn）披露 的相关公告。 根据《上市公司股份回购规则》《深圳证券交易所上市公司自律监管指引第 9 号——回购股份》等相关规定，公司在回购期间应当在每个月的前三个交易日 内公告截至上月末的回购进展情况。现将公司回购进展情况公告如下： 一 ...

Group 1 - The company has made strategic moves in the low-altitude economy sector by utilizing drones for product delivery [1]

Meeting Information - The company will hold its 2025 Fourth Extraordinary General Meeting on October 22, 2025, at 14:30 [2] - The meeting will be conducted both in-person and via online voting [3] - The record date for shareholders to attend the meeting is October 17, 2025 [4] Voting Process - Shareholders can vote through the Shenzhen Stock Exchange trading system and the internet voting system [3][12] - Voting times for the trading system are from 9:15-9:25, 9:30-11:30, and 13:00-15:00 on the meeting day [12] - The internet voting system will be available from 9:15 to 15:00 on the same day [14] Attendance Requirements - All ordinary shareholders registered by the record date can attend the meeting and may appoint a proxy [5] - The meeting will also include company directors, supervisors, senior management, and other relevant personnel [5] Registration Details - Registration for the meeting will take place on October 21, 2025, from 9:00-11:00 and 14:00-17:00 [7] - The registration location is at the company's office in Chongqing [7] Contact Information - For inquiries, shareholders can contact the company's securities department via phone or email [8]

Core Points - Chongqing Pharmaceutical (Group) Co., Ltd. has announced a total bank financing credit application of up to RMB 116.3 million for 40 wholly-owned subsidiaries for the year 2025 [2] - The company has also provided a maximum joint liability guarantee of up to RMB 614.836 million for 58 controlled subsidiaries for the same period [2] - An adjustment of guarantee limits for 8 subsidiaries has been proposed, resulting in a total reduction of RMB 18.9 million [2] - The actual credit limits and terms will be subject to approval by banks and financial institutions [2] - The board of directors has approved the adjustment proposal, which will be submitted for shareholder meeting review [2]

Group 1 - The core point of the article highlights that Zhongyao Holdings (SZ 000950) held its 18th meeting of the 9th board of directors on September 29, 2025, via telecommunication to discuss the proposal for the fourth extraordinary shareholders' meeting of 2025 [1] - For the first half of 2025, Zhongyao Holdings reported that its revenue composition was 94.81% from pharmaceutical wholesale, 4.73% from pharmaceutical retail, and 0.46% from other businesses [1] - As of the report date, Zhongyao Holdings had a market capitalization of 8.8 billion yuan [1] Group 2 - The article also discusses the competitive landscape in the beverage industry, noting that after the launch of the Farmer Green Bottle, Yibao experienced a significant decline in market share, dropping nearly 5 percentage points [1]

（一）日常关联交易概述 证券代码：000950 证券简称：重药控股 公告编号：2025-071 为保证公司日常经营的稳定持续运行，公司第九届董事会第十次会议及 2025 年第一次临时股东会审议通过了《关于 2024 年日常关联交易执行情况及 2025 年 日常关联交易预计的议案》，对公司 2025 年度与关联方日常关联交易进行了预计， 预计总金额为 156,750.00 万元。具体内容详见公司于 2024 年 12 月 21 日在巨潮资 讯网上披露的《关于 2024 年日常关联交易执行情况及 2025 年日常关联交易预计 的公告》（公告编号：2024-088）。 重药控股股份有限公司 关于增加2025年日常关联交易额度的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 一、日常关联交易基本情况 （二）本次增加情况 2025 年公司原预计与通用技术集团发生日常关联交易上限为 97,400 万元， 本次增加预计 50,000.00 万元，增加后 2025 年与通用技术集团发生日常关联交易 上限为 147,400.00 万元。本次增加情况如下： 单位：万元 公司 ...

证券代码：000950 证券简称：重药控股 公告编号：2025-072 重药控股股份有限公司 根据重药股份子公司2025年上半年实际经营与获取银行等金融机构授信 情况，拟对下属8家子公司担保额度进行调整，合计减少18,900万元，各公司 实际授信额度和期限最终以各银行等机构实际审批授信额度和期限为准，重 药股份按照《重庆医药（集团）股份有限公司担保管理办法》办理；具体情 况如下： 1 | 序 | 被担保人 | 控股股东 | 原担保金额 | 调整担保金 额（调减用 | 调整后担 | 调整担保额 | 调整金额是 否按股比担 | | --- | --- | --- | --- | --- | --- | --- | --- | | 号 | | 持股比例 | | | 保金额 | 度担保人 | | | | | | | "_"表示） | | | 保或有反担保 | | 1 | 重庆医药集团（宁 | 70% | 16,000 | 3,000 | 19,000 | 重药股份 | 按股比担保 | | | 夏）有限公司 | | | | | | | | | 新疆生产建设兵 | | | | | | | | 2 | 团医药有限责任 | ...